342 results on '"Glanz, Bonnie I."'
Search Results
2. Multiple sclerosis lesions that impair memory map to a connected memory circuit
3. Correction to: Clinical trial-ready patient cohorts for multiple system atrophy: coupling biospecimen and iPSC banking to longitudinal deep-phenotyping
4. Association between PROMIS10, SF-36 and NeuroQoL in persons with multiple sclerosis
5. Lesion network localization of depression in multiple sclerosis
6. Early neurofilament light and glial fibrillary acidic protein levels improve predictive models of multiple sclerosis outcomes
7. Patient-reported outcomes associated with transition to secondary progressive multiple sclerosis
8. Serum glial fibrillary acidic protein predicts disease progression in multiple sclerosis.
9. Identification of MS-specific serum miRNAs in an international multicenter study
10. Social support in multiple sclerosis: Associations with quality of life, depression, and anxiety
11. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes
12. The impact of cervical spinal cord atrophy on quality of life in multiple sclerosis
13. Time between expanded disability status scale (EDSS) scores
14. CE ARTICLE. Stigma in Multiple Sclerosis: A Narrative Review of Current Concepts, Measures, and Findings.
15. Increasing Neurofilament and Glial Fibrillary Acidic Protein After Treatment Discontinuation Predicts Multiple Sclerosis Disease Activity
16. Accuracy of serum neurofilament light to identify contrast-enhancing lesions in multiple sclerosis
17. Health-Related Quality of Life in Women with Multiple Sclerosis
18. Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate
19. Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis
20. The effect of alcohol and red wine consumption on clinical and MRI outcomes in multiple sclerosis
21. Quantifying neurologic disease using biosensor measurements in-clinic and in free-living settings in multiple sclerosis
22. The neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios are independently associated with neurological disability and brain atrophy in multiple sclerosis
23. Patient-reported outcomes in multiple sclerosis: Relationships among existing scales and the development of a brief measure
24. Correction to: Clinical trial-ready patient cohorts for multiple system atrophy: coupling biospecimen and iPSC banking to longitudinal deep-phenotyping
25. Serum NfL but not GFAP predicts cognitive decline in active progressive multiple sclerosis patients
26. Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes
27. Clinical Trial-Ready Patient Cohorts for Multiple System Atrophy: Coupling Biospecimen and iPSC Banking to Longitudinal Deep-Phenotyping
28. Estimating the association between physical activity and health-related quality of life in individuals with multiple sclerosis
29. Younger age at multiple sclerosis onset is associated with worse outcomes at age 50
30. The impact of a recent relapse on patient-reported outcomes in subjects with multiple sclerosis
31. Characterizing Clinical and MRI Dissociation in Patients with Multiple Sclerosis
32. Work Productivity in Relapsing Multiple Sclerosis: Associations with Disability, Depression, Fatigue, Anxiety, Cognition, and Health-Related Quality of Life
33. Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis
34. Early Predictors of Clinical and MRI Outcomes Using Least Absolute Shrinkage and Selection Operator (LASSO) in Multiple Sclerosis
35. sj-docx-1-mso-10.1177_20552173211069348 - Supplemental material for Serum NfL levels in the first five years predict 10-year thalamic fraction in patients with MS
36. Serum NfL levels in the first five years predict 10-year thalamic fraction in patients with MS
37. Whole Brain Volume Measured from 1.5T versus 3T MRI in Healthy Subjects and Patients with Multiple Sclerosis
38. Serum NfL but not GFAP predicts cognitive decline in active progressive multiple sclerosis patients.
39. The association between cognitive impairment and quality of life in patients with early multiple sclerosis
40. Patient-reported outcomes associated with transition to secondary progressive multiple sclerosis
41. Quantification of Global Cerebral Atrophy in Multiple Sclerosis from 3T MRI Using SPM: The Role of Misclassification Errors
42. sj-pdf-1-mso-10.1177_2055217321999070 - Supplemental material for Confirmed disability progression provides limited predictive information regarding future disease progression in multiple sclerosis
43. sj-pdf-2-mso-10.1177_20552173211015503 - Supplemental material for Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability
44. sj-pdf-1-mso-10.1177_20552173211015503 - Supplemental material for Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability
45. Abstracts from the ASENT 2010 annual meeting March 4–6, 2010
46. Abstracts from the ASENT 2008 Annual Meeting March 6–8, 2008
47. Gut Microbiome in Progressive Multiple Sclerosis
48. Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability
49. The impact of ocrelizumab on health-related quality of life in individuals with multiple sclerosis
50. Confirmed disability progression provides limited predictive information regarding future disease progression in multiple sclerosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.